百时美施贵宝2024年营收同比增长7% 预计今年成熟产品收入至少下降18%

每日经济新闻
07 Feb

2月6日,百时美施贵宝(BMS)公布2024年业绩,公司实现总营收483.00亿美元,同比增长7%;研发投入111.59亿美元,同比增长20%。  但是,BMS给出的业绩指引却低于分析师预估。公司预计2025年的营收约为455亿美元,成熟产品可能将面临18%—20%的收入下降,其中来那度胺(Revlimid)的收入可能较2024年减少一半多。  专利悬崖在前,如何寻找新药物?在今年1月的J.P....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10